title: Bone morphogenetic protein-2 inhibits differentiation and mineralization of cementoblasts in vitro.
abstract: As an approach for improving the outcome and predictability of periodontal regenerative therapies, we have focused on determining the responses of cells within the local environment to putative regenerative factors. This study examined the effects of bone morphogenetic protein-2 (BMP-2) on murine cementoblasts in vitro. Northern blot analysis indicated that BMP-2 decreased mRNA levels of bone sialoprotein and type I collagen dose-dependently (10-300 ng/mL). At low doses, up to 100 ng/mL, BMP-2 had no effect on transcripts for osteocalcin and osteopontin, whereas at 300 ng/mL, BMP-2 greatly increased expression of these two genes. BMP-2 also inhibited cementoblast-mediated mineral nodule formation in a dose-dependent manner (inhibition was noted at 10 ng/mL). Noggin reversed the effects of BMP-2 on gene expression and on mineralization. These findings reflect the diverse responses of periodontal cells to BMP-2 and highlight the need to consider the complexity of factors involved in designing predictable regenerative therapies.
authors.affiliation: Department of Periodontics/Prevention/Geriatrics, University of Michigan School of Dentistry, 1011 N University Avenue, Ann Arbor, MI 48109-1078, USA.
authors.forename: M
authors.initials: M
authors.lastname: Zhao
authors.forename: J E
authors.initials: JE
authors.lastname: Berry
authors.forename: M J
authors.initials: MJ
authors.lastname: Somerman
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D015153:Blotting, Western; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002352:Carrier Proteins; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D024042:Collagen Type I / Q000187:drug effects; D003739:Dental Cementum / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects; D058574:Integrin-Binding Sialoprotein; D051379:Mice; D008822:Mice, Transgenic; D008903:Minerals / Q000378:metabolism; D015675:Osteocalcin / Q000187:drug effects; D053495:Osteopontin; D010750:Phosphoproteins / Q000187:drug effects; D011506:Proteins / Q000494:pharmacology; D012333:RNA, Messenger / Q000187:drug effects; D012795:Sialoglycoproteins / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000099176:Noggin Protein
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002352:Carrier Proteins; D024042:Collagen Type I; D058574:Integrin-Binding Sialoprotein; D008903:Minerals; D015675:Osteocalcin; D053495:Osteopontin; D010750:Phosphoproteins; D011506:Proteins; D012333:RNA, Messenger; D012795:Sialoglycoproteins; D016212:Transforming Growth Factor beta; D000099176:Noggin Protein; C525719:Bmp2 protein, mouse; C546872:Ibsp protein, mouse; C506896:Spp1 protein, mouse